Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems and products. The company operates in Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products segments. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 15mg and 30mg capsules, and 37.5mg tablets for the treatment of bariatrics under Adipex-P brand name; Lodrane D immediate release capsules for OTC allergy treatment; Methadone HCl 10mg tablets for pains under the Dolophine name; and Hydromorphone HCl 8mg tablets for pains under the Dilaudid name. The company also provides Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril name; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia name; Isradipine 2.5mg and 5mg capsules for cardiovascular diseases; Hydroxyzine HCl 10mg, 25mg, and 50mg tablets for antihistamine treatment under Atarax and Vistaril brand names; Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone name; and Trimipramine Maleate Immediate Release 25mg, 50mg, and 100mg antidepressant capsules under the Surmontil brand, as well as SequestOX, an immediate release Oxycodone with Naltrexone. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. It has a manufacturing and license agreement with Epic Pharma LLC; manufacturing and supply agreement with The PharmaNetwork LLC; development and license agreement with SunGen Pharma, LLC; and strategic marketing alliance with Glenmark Pharmaceuticals, Inc. USA. The company was founded in 1984 and is headquartered in Northvale, New Jersey.
Read More
